| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
β-tubulin. Hemiasterlin binds to the Vinca-peptide site on β-tubulin and inhibits microtubule polymerization.
|
|---|---|
| ln Vitro |
With down to subnanomolar potency against numerous cancer cell lines, hemesterlin is an antimitotic drug that disrupts microtubule dynamics to cause mitotic arrest and cell death [1].
Hemiasterlin exhibits remarkable cytotoxicity against various cancer cell lines with sub-nanomolar potency. It binds to tubulin, inhibits microtubule polymerization, and induces mitotic arrest. Its mechanism of action is distinct from other microtubule-targeting agents like taxanes. The compound disrupts microtubule dynamics to cause mitotic arrest and cell death. |
| ln Vivo |
Hemiasterlin demonstrates potent antitumor activity in vivo as a cytotoxic payload in antibody-drug conjugates (ADCs). By inducing mitotic arrest and abnormal spindle formation, it causes cell death in target cells. The compound has been incorporated into ADCs for targeted therapeutic applications.
|
| Enzyme Assay |
In vitro tubulin polymerization assays are used to evaluate the activity of hemiasterlin. Purified tubulin is incubated under conditions that promote polymerization (such as the presence of GTP and warm temperature) in the presence or absence of the compound. Polymerization is monitored spectrophotometrically by measuring turbidity at 340 nm. The compound's inhibition of polymerization is measured as a reduction in the rate or extent of tubulin assembly.
|
| Cell Assay |
In vitro cell-based assays for hemiasterlin evaluate its cytotoxic activity against various cancer cell lines. Cells are treated with varying concentrations of the compound, and cell viability is assessed after 48-72 hours using standard assays such as MTT, CellTiter-Glo, or sulforhodamine B. IC₅₀ values are determined from dose-response curves. Cell cycle analysis by flow cytometry confirms mitotic arrest.
|
| Animal Protocol |
In vivo animal studies for hemiasterlin are typically conducted in mouse xenograft models where human tumor cells are implanted subcutaneously. The compound, often as an ADC payload, is administered intravenously and tumor growth inhibition is monitored. In vivo efficacy is demonstrated by reduction in tumor volume compared to vehicle control. Pharmacodynamic markers of mitotic arrest and apoptosis are assessed in tumor tissue.
|
| ADME/Pharmacokinetics |
Hemiasterlin is a cytotoxic compound with a molecular weight of approximately 536.75 g/mol. As a peptide, it is typically administered intravenously when used as an ADC payload. Detailed pharmacokinetic properties of the free drug are not extensively reported, as the compound is primarily used as a payload in ADCs where its pharmacokinetics are determined by the antibody conjugate.
|
| Toxicity/Toxicokinetics |
Hemiasterlin is a highly cytotoxic compound that induces mitotic arrest and cell death. As a potent inhibitor of tubulin polymerization, it has significant toxicity towards rapidly dividing cells. When used as an ADC payload, toxicity is targeted to cells expressing the antigen recognized by the antibody. The compound is classified as a research-grade chemical and is not intended for human use as a free drug.
|
| References | |
| Additional Infomation |
According to reports, stromalin has been found in both Cymbastela and Siphonochalina, and relevant data are available for reference.
Hemiasterlin (CAS# 157207-90-4) is a sponge-derived antimitotic tripeptide that binds to the Vinca-peptide site on β-tubulin and inhibits microtubule polymerization. It exhibits sub-nanomolar cytotoxicity against cancer cell lines. The compound is used as a cytotoxic payload in antibody-drug conjugates (ADCs) for targeted cancer therapy. Its mechanism is distinct from taxanes. It has not received FDA approval as a free drug. |
| Molecular Formula |
C30H46N4O4
|
|---|---|
| Molecular Weight |
526.72
|
| Exact Mass |
526.352
|
| CAS # |
157207-90-4
|
| PubChem CID |
5352092
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.319
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
38
|
| Complexity |
891
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CC(C)[C@@H](/C=C(\C)/C(=O)O)N(C)C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C(C)(C)C1=CN(C2=CC=CC=C21)C)NC
|
| InChi Key |
KQODQNJLJQHFQV-MKWZWQCGSA-N
|
| InChi Code |
InChI=1S/C30H46N4O4/c1-18(2)23(16-19(3)28(37)38)34(11)27(36)25(29(4,5)6)32-26(35)24(31-9)30(7,8)21-17-33(10)22-15-13-12-14-20(21)22/h12-18,23-25,31H,1-11H3,(H,32,35)(H,37,38)/b19-16+/t23-,24-,25-/m1/s1
|
| Chemical Name |
(E,4S)-4-[[(2S)-3,3-dimethyl-2-[[(2S)-3-methyl-2-(methylamino)-3-(1-methylindol-3-yl)butanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid
|
| Synonyms |
Milnamide B; NSC695242; Hemiasterlin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~189.86 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.75 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.75 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.75 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8985 mL | 9.4927 mL | 18.9854 mL | |
| 5 mM | 0.3797 mL | 1.8985 mL | 3.7971 mL | |
| 10 mM | 0.1899 mL | 0.9493 mL | 1.8985 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
